Weil’s Antitrust team is representing Actavis in its just announced acquisition of Allergan, a transaction valued at $66 billion.
The transaction is expected to close in the second quarter of 2015 pending approval of the shareholders of both companies, as well as receiving antitrust clearance in the United States, the European Union and certain other jurisdictions.
Weil previously served as antitrust counsel to Forest Laboratories Inc. in its $24.2 billion sale to Actavis, Inc.
Weil’s Antitrust team includes partners Steve Newborn and Ann Malester, counsel John Sipple, associates Brianne Kucerik and Alexis Brown-Reilly, and Kristin Sanford (not yet admitted to practice).
Source: www.weil.com
